Use access key #2 to skip to page content.
  • S&P 500: 1,091.38
  • Change: -0.32%
$0.74 -0.05 (-6.46%)
11/20/2009 4:00 PM

XOMA Limited (XOMA)

CAPS Rating:
***

A biopharmaceutical company that discovers, develops and manufactures antibodies and other genetically-engineered protein products to treat immunological and inflammatory disorders, cancer and infectious diseases.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

Ticker Not Ratable

XOMA doesn't currently meet the $100M market cap / $1.50 stock price minimum. (Learn More)

What the Community Thinks

Total Members

252 Outperforms
18 Underperforms
 

All-Stars

25 Outperforms
6 Underperforms
 

Wall Street

8 Outperforms
0 Underperforms
 

Members bullish on XOMA are also bullish on:

Members bearish on XOMA are also bearish on:

Ticker Tags

Biotechnology (225), Defensive (1498), Growth (1883), Distressed (1623), Healthcare (733), Micro Cap (4867)
Suggest a tag

XOMA Limited At A Glance

Current Price: $0.74
Last Trade Time: 11/20/2009 4:00 PM
Open: $0.70
Previous Close: $0.79
Daily Range: $0.70 - $0.76
52-Week Range: $0.37 - $1.34
Volume: 2,415,049
Market Cap: $147.01M
P/E Ratio: 13.17
Compare Our Special Broker Offers!

Stock Trends

XOMA VS S&P 500 (SPY)

News & Discussion Boards

Top Bull Pitch

Recs

2

XOMA Limited (XOMA)

Avatar 1FastTurtle (76.03) Submitted: 1/16/09 2:33 PM

Doing all the right things to survive and still proceed with their best chance at a big time drug. Phase 2 and 3 trials will be crucial to their survival.

Replies: 0 | Reply | Permalink

Top Bear Pitch

Recs

2

XOMA Limited (XOMA)

Avatar BrianRuth (99.21) Submitted: 3/05/07 2:16 AM

Calling BS on this one. It would be great if they could help cancer with recombinant whatever, but I think 9 out of 10 microcap companies in this space will go bankrupt.

Replies: 1 | Reply | Permalink

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 48 :   1 2 3 4 5 Next » Jump to page:

Recs

2

 (XOMA)

Avatar 1FastTurtle (76.03) Submitted: 1/16/09 2:33 PM : Outperform Start Price: $2.54 XOMA Score: -57.76

Doing all the right things to survive and still proceed with their best chance at a big time drug. Phase 2 and 3 trials will be crucial to their survival.

Report this Post Replies: 0 | Reply | Permalink

Recs

1

 (XOMA)

Avatar GreatDana (54.73) Submitted: 10/22/08 4:00 AM : Outperform Start Price: $1.59 XOMA Score: -73.91

Antibodies = diabetes+cureall

Report this Post Replies: 0 | Reply | Permalink

Recs

1

 (XOMA)

Avatar jungleeater (< 20) Submitted: 8/25/08 5:05 PM : Outperform Start Price: $1.99 XOMA Score: -51.73

XOMA has a couple of good products in the works---R&D is a snail pace endeavor...and with the Government thrown into the mix some drugs take forever to materialize---better to err for the sake of safety but .....

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (XOMA)

Avatar rvood (< 20) Submitted: 7/23/08 12:49 AM : Outperform Start Price: $2.29 XOMA Score: -56.02

Good pipeline, royalties working, good relationships with big Pharma, would speculate as to a possible buyout.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (XOMA)

Avatar WILLWYKO777 (< 20) Submitted: 7/06/08 6:05 PM : Outperform Start Price: $1.66 XOMA Score: -44.52

already have drug pipeline royalities, drugs in the wings are very promising, they are a buyout canidate

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 48 :   1 2 3 4 5 Next » Jump to page:

Wall Street

Results 1 - 8 of 8  

picks per page. CHANGE

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackPacificGrow 81.63 07/29/08 Outperform NS $1.94-61.91%-8.96%-52.95
TrackSusquehanna 73.96 05/13/08 Outperform NS $2.15-65.63%-19.17%-46.46
TrackLadenburg 36.87 05/12/08 Outperform NS $2.14-65.47%-19.13%-46.34
TrackPZK < 20 03/25/08 Outperform NS $2.65-72.11%-15.47%-56.64
TrackRBCCapMkts 82.07 03/05/08 Outperform NS $2.61-71.68%-14.52%-57.17
TrackCanaccord 78.23 11/27/07 Outperform NS $3.08-76.01%-19.11%-56.89
TrackJimCramer 36.31 10/03/07 Outperform 3W $3.85-80.81%-25.45%-55.36
TrackRodmanRen < 20 01/24/07 Outperform NS $2.51-70.56%-18.32%-52.24

Results 1 - 8 of 8  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners

EQWEBD04 515ms